Citations

Clear

499 citation(s) found for "Tracy, PB".

Features and Outcomes of Patients Who Underwent Cardiac Device Deactivation
Buchhalter, Lillian C., Ottenberg, Abigale L., Webster, Tracy L., Hayes, David L. , Mueller, Paul S. , Swetz, Keith M.

Mayo Clinic

JAMA Internal Medicine | November 25, 2013 | Volume: 174 | Issue: 1 | Pages: 80

10.1001/jamainternmed.2013.11564 | PMID 24276835 Get It

HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation
Baker, Jason V. , Brummel‐Ziedins, Kathleen E., Neuhaus, Jacqueline, Dalmau, David , Lehmann, Clara , Sullivan, Ann , Woolley, Ian , Kuller, Lewis H. , Neaton, James D. , Team, INSIGHT SMART Study, Duprez, Daniel A. , Cummins, Nathan W. , DeHovitz, Jack A. , Tracy, Russell P. , Team, INSIGHT SMART Study, Nordwall, Jacqueline

Mayo Clinic

Journal of the American Heart Association | July 29, 2013 | Volume: 2 | Issue: 4 | Pages: No page available

10.1161/jaha.113.000264 | PMID 23896681 Get It

Background HIV infection leads to activation of coagulation, which may increase the risk for atherosclerosis and venous thromboembolic disease. We hypothesized that HIV replication increases coagulation potentially through alterations in extrinsic pathway factors. Methods and Results Extrinsic pathway factors were measured among a subset of HIV participants from the Strategies for Management of Anti‐Retroviral Therapy ( SMART ) trial. Thrombin generation was estimated using validated computational modeling based on factor composition. We characterized the effect of antiretroviral therapy ( ART ) treatment versus the untreated state ( HIV replication) via 3 separate analyses: (1) a cross‐sectional comparison of those on and off ART (n=717); (2) a randomized comparison of deferring versus starting ART (n=217); and (3) a randomized comparison of stopping versus continuing ART (n=500). Compared with viral suppression, HIV replication consistently showed short‐term increases in some procoagulants (eg, 15% to 23% higher FVIII ; P <0.001) and decreases in key anticoagulants (eg, 5% to 9% lower antithrombin [ AT ] and 6% to 10% lower protein C; P <0.01). The net effect of HIV replication was to increase coagulation potential (eg, 24% to 48% greater thrombin generation from computational models; P <0.01 for all). The pattern of changes from HIV replication was reversed with ART treatment and consistent across all 3 independent comparisons. Conclusions HIV replication leads to complex changes in extrinsic pathway factors, with the net effect of increasing coagulation potential to a degree that may be clinically relevant. The key influence of changes in FVIII and AT suggests that HIV ‐related coagulation abnormalities may involve changes in hepatocyte function in the context of systemic inflammation. Clinical Trial Registration URL: ClinicalTrials.gov . Unique identifier: NCT 00027352.
A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
Tang, Weihong , Heit, John A. , Morange, Pierre‐Emmanuel , Pankratz, Nathan , Leebeek, Frank W.G. , Paré, Guillaume , Tzourio, Christophe , Basu, Saonli , Rose, Lynda M., Armasu, Sebastian M. , Lumley, Thomas, Heckbert, Susan R. , Uitterlinden, André G. , Lathrop, Mark, Cushman, Mary , Hofman, Albert , Lambert, Jean‐Charles , Glazer, Nicole L. , Pankow, James S. , Witteman, Jacqueline C.M., Amouyel, Philippe , Bis, Joshua C. , Bovill, Edwin G., Kong, Xiaoxiao , Boerwinkle, Eric , Trégouët, David‐Alexandre , Loth, Daan W. , Stricker, Bruno H. , Folsom, Aaron R. , Smith, Nicholas L. , Teichert, Martina , Chasman, Daniel I. , Guo, Li , Andrade, Mariza de , Psaty, Bruce M. , Ruiter, Rikje , Rice, Kenneth , Tracy, Russell P. , Rotter, Jerome I. , Ridker, Paul M. , Amouyel, Philippe , Tzourio, Christophe , Pankratz, Nathan , Pankow, James S , Tang, Weihong , Paré, Guillaume

Mayo Clinic

Genetic Epidemiology | May 5, 2013 | Volume: 37 | Issue: 5 | Pages: 512-521

10.1002/gepi.21731 | PMID 23650146 Get It

ABSTRACTVenous thromboembolism (VTE) is a common, heritable disease resulting in high rates of hospitalization and mortality. Yet few associations between VTE and genetic variants, all in the coagulation pathway, have been established. To identify additional genetic determinants of VTE, we conducted a two‐stage genome‐wide association study (GWAS) among individuals of European ancestry in the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) VTE consortium. The discovery GWAS comprised 1,618 incident VTE cases out of 44,499 participants from six community‐based studies. Genotypes for genome‐wide single‐nucleotide polymorphisms (SNPs) were imputed to approximately 2.5 million SNPs in HapMap and association with VTE assessed using study‐design appropriate regression methods. Meta‐analysis of these results identified two known loci, in F5 and ABO. Top 1,047 tag SNPs (P ≤ 0.0016) from the discovery GWAS were tested for association in an additional 3,231 cases and 3,536 controls from three case‐control studies. In the combined data from these two stages, additional genome‐wide significant associations were observed on 4q35 at F11 (top SNP rs4253399, intronic to F11) and on 4q28 at FGG (rs6536024, 9.7 kb from FGG; P < 5.0 × 10−13 for both). The associations at the FGG locus were not completely explained by previously reported variants. Loci at or near SUSD1 and OTUD7A showed borderline yet novel associations (P < 5.0 × 10−6) and constitute new candidate genes. In conclusion, this large GWAS replicated key genetic associations in F5 and ABO, and confirmed the importance of F11 and FGG loci for VTE. Future studies are warranted to better characterize the associations with F11 and FGG and to replicate the new candidate associations.
Teaching Neuro Images : PET-CT hypermetabolism paralleling muscle hyperactivity in stiff-person syndrome
O’Toole, Orna , Tracy, Jennifer A., McKeon, Andrew , Murphy, Robert L. , McKeon, Andrew

Mayo Clinic

Neurology | March 5, 2013 | Volume: 80 | Issue: 10 | Pages: No page available

10.1212/wnl.0b013e3182840bad | PMID 23460625 Get It

Frequency and spectrum of myopathies in patients with psoriasis
Liewluck, Teerin , Ernste, Floranne C. , Tracy, Jennifer A., Liewluck, T

Mayo Clinic

Muscle & Nerve | February 8, 2013 | Volume: 48 | Issue: 5 | Pages: 716-721

10.1002/mus.23812 | PMID 24037820 Get It

Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease
Yab, Tracy C. , Hussain, Fareeda Taher Nazer, Garrity-Park, Megan, Sandborn, William J. , Loftus, Edward V. , Wolff, B. G., Smyrk, Thomas C. , Zou, Hongzhi , Ahlquist, David A. , Kisiel, John B. , Taylor, William R. , Itzkowitz, Steven H. , Rubin, David T. , Mahoney, Douglas W. , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 24, 2013 | Volume: 37 | Issue: 5 | Pages: 546-554

10.1111/apt.12218 | PMID 23347191 Get It

SummaryBackgroundCurrent approaches to the detection of colorectal neoplasia associated with inflammatory bowel disease (IBD‐CRN) are suboptimal.AimTo test the feasibility of using stool assay of exfoliated DNA markers to detect IBD‐CRN.MethodsThis investigation comprised tissue and stool studies. In the tissue study, gene sequencing and methylation assays were performed on candidate genes using tissue DNA from 25 IBD‐CRNs and from 25 IBD mucosae without CRN. Mutations on p53, APC, KRAS, BRAF or PIK3CA genes were insufficiently informative, but several aberrantly methylated genes were highly discriminant. In the stool study, we evaluated candidate methylated genes (vimentin, EYA4, BMP3, NDRG4) in a prospective blinded study on buffered stools from 19 cases with known IBD‐CRN and 35 age‐ and sex‐matched IBD controls without CRN. From stool‐extracted DNA, target genes were assayed using quantitative allele‐specific real‐time target and signal amplification method.ResultsIBD‐CRN cases included 17 with ulcerative colitis (UC) and two with Crohn's disease (CD); nine had cancer and 10 had dysplasia. Controls included 25 with UC and 10 with CD. Individually, BMP3, vimentin, EYA4 and NDRG4 markers showed high discrimination in stools with respective areas under the ROC curve of 0.91, 0.91, 0.85 and 0.84 for total IBD‐CRN and of 0.97, 0.97, 0.95 and 0.85 for cancer. At 89% specificity, the combination of BMP3 and mNDRG4 detected 9/9 (100%) of CRC and 80% of dysplasia, 4/4 (100%) of high grade and 4/6 (67%) of low grade.ConclusionThese findings demonstrate the feasibility of stool DNA testing for non‐invasive detection of colorectal neoplasia associated with inflammatory bowel disease.
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
Pardanani, Animesh , Akin, Cem , Reiter, Andreas , George, Tracy I. , Hermine, Olivier , Kluin‐Nelemans, Hanneke C. , Hartmann, Karin , Sperr, Wolfgang R. , Schwartz, Lawrence B. , Arock, Michel , Sotlar, Karl , Horny, Hans-Peter, Metcalfe, Dean D. , Escribano, Luís, Verstovšek, Srđan , Tefferi, Ayalew , Valent, Peter , Gotlib, Jason , Brockow, Knut , Órfão, Alberto , DeAngelo, Daniel J. , Verstovsek, Srdan , George, Tracy I , Sperr, Wolfgang , Valent, Peter , Hermine, Olivier , Akin, Cem , Arock, Michel , Kluin-Nelemans, Hanneke C

Mayo Clinic

Blood | January 17, 2013 | Volume: 121 | Issue: 13 | Pages: 2393-2401

10.1182/blood-2012-09-458521 | PMID 23325841 Get It

Abstract Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.
Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized With Acute Heart Failure
Kociol, Robb D. , McNulty, Steven E., Hernandez, Adrian F. , Lee, Kerry L. , Redfield, Margaret M. , Braunwald, Eugene, O’Connor, Christopher M. , Felker, G. Michael , Tracy, Russell P. , Hernandez, Adrian

Mayo Clinic

Circulation: Heart Failure | December 19, 2012 | Volume: 6 | Issue: 2 | Pages: 240-245

10.1161/circheartfailure.112.969246 | PMID 23250981 Get It

Background— Congestion is a primary driver of symptoms in patients with acute heart failure, and relief of congestion is a critical goal of therapy. Monitoring of response to therapy through the assessment of daily weights and net fluid loss is the current standard of care, yet the relationship between commonly used markers of decongestion and both patient reported symptom relief and clinical outcomes are unknown. Methods and Results— We performed a retrospective analysis of the randomized clinical trial, Diuretic Optimization Strategy Evaluation in Acute Heart Failure (DOSE-AHF), enrolling patients hospitalized with a diagnosis of acute decompensated heart failure. We assessed the relationship among 3 markers of decongestion at 72 hours—weight loss, net fluid loss, and percent reduction in serum N terminal B-type natriuretic peptide (NT-proBNP) level—and relief of symptoms as defined by the dyspnea visual analog scale area under the curve. We also determined the relationship between each marker of decongestion and 60-day clinical outcomes defined as time to death, first rehospitalization or emergency department visit. Mean age was 66 years, mean ejection fraction was 35%, and 27% had ejection fraction ≥50%. Of the 3 measures of decongestion assessed, only percent reduction in NT-proBNP was significantly associated with symptom relief ( r =0.13; P =0.04). There was no correlation between either weight loss or net fluid loss and symptom relief, ( r =0.04; P =0.54 and r =0.07; P =0.27, respectively). Favorable changes in each of the 3 markers of decongestion were associated with improvement in time to death, rehospitalization, or emergency department visit at 60 days (weight: hazard ratio, 0.91; 95% confidence interval, 0.85–0.97 per 4 lbs; weight lost; fluid hazard ratio, 0.94; 95% confidence interval, 0.90–0.99 per 1000 mL fluid loss; NT-proBNP hazard ratio, 0.95; 95% confidence interval, 0.91–0.99 per 10% reduction). These associations were unchanged after multivariable adjustment with the exception that percent reduction in NT-proBNP was no longer a significant predictor (hazard ratio, 0.97; 95% confidence interval, 0.93–1.02). The rates of death, HF hospitalization, or emergency department visit at 60 days for patients with 0, 1, 2, and 3 markers of decongestion (above the median) were 67%, 64%, 46%, and 38%, respectively (log rank P value=0.05). Figure. Relationship between number of markers of decongestion above median* and time to 60-day risk of emergency department (ED) visit, rehospitalization, or death. *Median net fluid loss, 3.8 L; median net weight loss, 6.5 lbs; median percent reduction in N terminal B-type natriuretic peptide 24.3%. Conclusions— Weight loss, fluid loss, and NT-proBNP reduction at 72 hours are poorly correlated with dyspnea relief. However, favorable improvements in each of the 3 markers were associated with improved clinical outcomes at 60 days. These data suggest the need for ongoing research to understand the relationships among symptom relief, congestion, and outcomes in patients with acute decompensated heart failure. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00577135.